Fig. 6
Effects of LGZG on STING-TBK1-NF-κB pathway in BMDMs. a, b Concentration of IFNβ (a) and TNFα (b) from the culture media of BMDMs treated with DMXAA, LPS and two doses of LGZG. BMDMs were treated with DMXAA (75 mg/mL) or control (7.5% NaHCO3) with or without LGZG (LGZG-L: 10−4or LGZG-H: 10–3 g/mL) for 24 h in the absence or presence of LPS (100 ng/mL). c Immunoblotting analysis of the expression of TBK1, p-TBK1 and STING. d Quantification of protein levels of STING and TNFα. e Quantification of p-TBK1/TBK1 levels. The data are expressed as mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 vs. DMXAA + LPS